Hims and Hers slides after revenue misses estimates amid GLP-1 scrutiny

Hims and Hers Health shares fell 14% in premarket trading after the company reported second-quarter revenue of $544.8 million, missing Wall Street estimates, amid escalating legal and regulatory scrutiny over its compounded GLP-1 weight-loss drugs. This key segment saw sequential revenue decline to $190 million from $230 million, driven by increased pressure from Novo Nordisk and the FDA's declaration that the semaglutide shortage has ended. While adjusted EPS beat expectations, analysts note a strategic transition for Hims, shifting focus away from the challenged GLP-1 business towards other areas like sexual health. The company's Q3 and full-year revenue guidance largely aligns with analyst consensus despite these headwinds.

Analysis

Hims & Hers Health (HIMS) is facing significant headwinds, evidenced by a 14% premarket share decline following its second-quarter report. The company's revenue of $544.8 million missed the consensus estimate of $549.9 million, driven by a sharp contraction in its key GLP-1 weight-loss drug business. This segment's online revenue fell sequentially to $190 million from $230 million in the prior quarter. The decline is directly attributable to mounting regulatory and legal pressure. The FDA has declared an end to the semaglutide shortage, removing the primary justification for pharmacies to sell compounded versions, and has advised firms to cease mass sales. Concurrently, Novo Nordisk (NVO) has intensified its legal actions against sellers of compounded semaglutide, which it deems "unlawful and unsafe," and has terminated its partnership with Hims. While the company's adjusted EPS of $0.17 beat expectations by two cents and its Q3 and full-year revenue guidance bracketed analyst consensus, the outlook is clouded by what analysts at Needham term a "state of transition." Hims is now actively winding down its GLP-1 revenue stream and shifting strategic focus toward its sexual health business, signaling a fundamental pivot away from a challenged growth driver.

Key Decisions for Investors

• Investors should recognize the significant regulatory and legal risks surrounding Hims' GLP-1 business, as the FDA's updated stance and Novo Nordisk's litigation create substantial uncertainty for this previously key revenue stream.
• It is critical to monitor the performance of Hims' non-GLP-1 segments, particularly the sexual health business, as the success of this strategic pivot is essential to offset the material decline in weight-loss drug sales.
• Despite the in-line guidance, the sharp sequential revenue drop in the GLP-1 segment warrants a reassessment of the company's growth trajectory and valuation, factoring in the heightened risk profile and business model transition.
• The aggressive legal posture from Novo Nordisk signals a broader industry crackdown on compounded drugs, suggesting potential headwinds for any telehealth platform with exposure to this market.